Quimilza (imsidolimab)
Vanda Pharmaceuticals (VNDA)
Decision dateDec 12, 2026
27 days away
Marketer take
Would be a second biologic for generalized pustular psoriasis after Spevigo, so dermatologists will hear differentiation messaging in a rare disease where recognizing GPP flares is still a core education need.
- Sponsor company
- Vanda Pharmaceuticals (VNDA)
- Indication
- Generalized pustular psoriasis (GPP)
- Therapeutic area
- Dermatology, Rare disease
- Event
- PDUFA target action date
- Date
- Dec 12, 2026
- Status
- Upcoming
- Source
- SEC filing
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?